APA Citation

Yi, Z., Ma, F., Liu, B., Guan, X., Li, L., Li, C., . . . Xu, B. (2019). Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. BMC Cancer.

Chicago Style Citation

Yi, Zongbi, Fei Ma, Binliang Liu, Xiuwen Guan, Lixi Li, Chunxiao Li, Haili Qian, and Binghe Xu. "Everolimus in Hormone Receptor-positive Metastatic Breast Cancer: PIK3CA Mutation H1047R Was a Potential Efficacy Biomarker in a Retrospective Study." BMC Cancer 2019.

MLA Citation

Yi, Zongbi, et al. "Everolimus in Hormone Receptor-positive Metastatic Breast Cancer: PIK3CA Mutation H1047R Was a Potential Efficacy Biomarker in a Retrospective Study." BMC Cancer 2019.

Warning: These citations may not always be 100% accurate.